{"id":11811,"date":"2023-12-13T11:27:01","date_gmt":"2023-12-13T03:27:01","guid":{"rendered":"https:\/\/vaxlab.dukekunshan.edu.cn\/?post_type=evidence-db-expert&p=11811"},"modified":"2024-08-12T16:03:00","modified_gmt":"2024-08-12T08:03:00","slug":"global-vaccination-coverage","status":"publish","type":"evidence-db-expert","link":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/evidence-db-expert\/hpv-vaccine-policy-advocacy-evidence-repository\/global-vaccination-coverage\/","title":{"rendered":"Global vaccination coverage"},"content":{"rendered":"\n

According to WHO and UNICEF\u2019s estimation, the global coverage of HPV vaccine in 2022 was as follows: 21% for the first dose and 15% for full immunization in females in the target prioritized age group (generally 9-14 years), and 6% for the first dose and 5% for full vaccination in males. Globally, 21% of 15-year-old girls received the first dose of HPV vaccines, and 17% were fully vaccinated, compared with 7% and 5% of that among boys, respectively. As shown in Figure 1<\/strong>, in 2019, the first dose coverage for females in high-income countries was 50% (95% CI: 35%-63%), and full immunization coverage was 40% (95% CI: 28%-53%). The first dose coverage for females in low- and middle-income countries was 16% (95% CI: 8%-31%), and full immunization coverage was 12% (95% CI: 5%- 24%). [1].<\/p>\n\n\n\n

Figure 1.<\/strong> <\/strong>Country-specific HPV vaccination program coverage estimates for girls by income level in 2019.<\/strong><\/p>\n\n\n

\n
\"\"
(Image source: Bruni, L., et al (2021). HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Preventive Medicine, 144, 106399.)<\/em><\/figcaption><\/figure>\n<\/div>\n\n\n

In low- and middle-income countries, international organizations often fund demonstration or pilot programs. Although they covered limited areas (often one region per country), the first dose coverage can be 93%, while the 2 or 3 dose rate can be as high as 70-90% [2]. The median of the first dose coverage is slightly higher in low- and middle-income countries (80%) compared with in high-income countries (72%), but the mean value of the proportion in LMICs who gave up the subsequent doses after the first dose is higher than those in high-income countries (18% vs 11%).<\/p>\n\n\n\n

Regarding regional distribution, only one-third of countries in sub-Saharan Africa have included HPV vaccines in their national immunization programs in 2022. The first dose coverage in the region has reached 33% and nearly 22% for full immunization. In contrast, Asian countries have the lowest HPV vaccine coverage, with less than 6% for the first dose and less than 4% for full immunization. The coverage also varies within countries, influenced by vaccine accessibility, the implementation of vaccine immunization programs, and the population’s willingness to be vaccinated.<\/p>\n\n\n\n

\n\n\n\n

Content Reviewer: Kelly Hunter, Tianyi Deng<\/p>\n\n\n\n

Page Editor: Jiaqi Zu<\/p>\n\n\n\n

\n\n\n\n

References:<\/strong><\/p>\n\n\n\n

    \n
  1. Bruni L, Saura-L\u00e1zaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, Afsar OZ, LaMontagne DS, Mosina L, Contreras M: HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019<\/strong>. Preventive Medicine <\/em>2021, 144<\/strong>:106399.<\/li>\n\n\n\n
  2. Gallagher KE, LaMontagne DS, Watson-Jones D: Status of HPV vaccine introduction and barriers to country uptake<\/strong>. Vaccine <\/em>2018, 36<\/strong>(32):4761-4767.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    According to WHO and UNICEF\u2019s estimation, the global coverage of HPV vaccine in 2022 was as follows: 21% for the first dose and 15% for full immunization in females in the target prioritized age group (generally 9-14 years), and 6% for the first dose and 5% for full vaccination in males. Globally, 21% of 15-year-old […]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":11287,"menu_order":0,"template":"","format":"standard","meta":{"articles_list_all":"","type_label":"none_selected"},"evidence-tag-expert":[104],"class_list":["post-11811","evidence-db-expert","type-evidence-db-expert","status-publish","format-standard","hentry","evidence-tag-expert-hpv"],"_links":{"self":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/evidence-db-expert\/11811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/evidence-db-expert"}],"about":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/types\/evidence-db-expert"}],"author":[{"embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/users\/5"}],"up":[{"embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/evidence-db-expert\/11287"}],"wp:attachment":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/media?parent=11811"}],"wp:term":[{"taxonomy":"evidence-tag-expert","embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/evidence-tag-expert?post=11811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}